Skip to Content

Merck KGaA ADR MKKGY Stock Quote

| Rating as of

Morningstar‘s Stock Analysis MKKGY

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Merck KGaA Turns In Strong Q2 Including Currency Rate Benefits; No Change to Fair Value Estimate

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Merck KGaA revealed solid second-quarter results and a slightly higher outlook than we had been incorporating into our model for 2022. Even after recognizing those decent trends in our model, though, we do not anticipate changing our fair value estimate at first glance. The shares continue to trade at moderately rich levels, in our opinion.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MKKGY

Company Profile MKKGY

Business Description

Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Contact
Frankfurter Strasse 250
Darmstadt, HE, 64293, Germany
T +49 6151720
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type
Employees 62,770